Most Recent
Take-Two interactive has won an injunction blocking a Grand Theft Auto gamer from distributing software that allows users to access restricted features of the popular game, a month after reaching a settlement with a gamer in a separate copyright case.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world's best-selling vaccine.
A Melbourne computer retailer that plans to appeal a $2.8 million fine for allegedly violating Microsoft's Windows 7 IP has won a stay of the court's order, with a judge finding the court's delay in publishing reasons for judgment created an "unsatisfactory state of affairs".
An IVF clinic that pioneered the use of artificial intelligence for embryo selection has sued a rival clinic for allegedly copying an advertising campaign featuring the slogan "more chubby cheeks".
A popular Australian designer of neoprene athleisure handbags has filed a lawsuit against another designer for making bags that allegedly copy the design of its trendy totes.
The Department of Agriculture and Water Resources has proposed a wine label directory meant to safeguard the intellectual property of Australian wine makers by making it easier to detect and bring lawsuits against copycats.
A Melbourne retailer is challenging a $2.8 million fine against it for allegedly violating the intellectual property for Microsoft's Windows 7 software.
A patent for genome editing technology by a South Korean biotechnology company has been rejected for a lack of clarity, novelty, and inventiveness, but the Australian Patent Office has given the company two months to try again.
Bega has admitted to allegations by Kraft that it distributed its peanut butter in boxes with the Kraft logo on the outside, but says it was allowed to under a license agreement.
Generic drug company Alphapharm has lost a bid for documents it claimed would show Sanofi-Aventis suspected as early as 2015 that patents for one of its injector pens may be invalid.